방사성 리간드 요법 시장 보고서(2026년)

Radioligand therapy (RLT) is an advanced targeted cancer treatment that combines a radioactive isotope with a ligand engineered to bind specifically to cancer cell receptors. Once administered, it locates tumor cells and delivers radiation directly to them, minimizing harm to healthy tissues. This targeted strategy helps reduce side effects and improve outcomes, especially in cancers resistant to conventional therapies.

The main types of radioligands in radioligand therapy include alpha emitters, beta emitters, Auger emitters, and combined emissions. Alpha emitters release high-energy alpha particles over very short distances, typically just a few cell layers, making them highly effective for precise cell destruction. These radioligands target specific molecular markers such as hormone receptors, growth factor receptors, and tumor antigens, and can be administered via intravenous (IV), intramuscular (IM), subcutaneous, or oral routes. Radioligand therapy is applied in oncological, cardiovascular, neurological, and infectious disease treatments, and is utilized by hospitals, diagnostic laboratories, research institutions, and home care settings.

Tariffs have impacted the radioligand therapy market by increasing costs of imported radioactive isotopes, ligands, and specialized delivery equipment. Segments like alpha and beta emitter therapies are most affected, particularly in regions like North America and Europe, where imports dominate supply chains. This has led to higher treatment costs and potential delays in therapy availability. On the positive side, tariffs have encouraged local production, investment in domestic radiopharmaceutical facilities, and innovation in cost-efficient RLT solutions.

The radioligand therapy market research report is one of a series of new reports from The Business Research Company that provides radioligand therapy market statistics, including radioligand therapy industry global market size, regional shares, competitors with a radioligand therapy market share, detailed radioligand therapy market segments, market trends and opportunities, and any further data you may need to thrive in the radioligand therapy industry. This radioligand therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The radioligand therapy market size has grown rapidly in recent years. It will grow from $6.63 billion in 2025 to $7.32 billion in 2026 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to limited availability of radioligands, reliance on conventional cancer therapies, growing awareness of targeted therapy benefits, increasing hospital adoption of nuclear medicine techniques, regulatory approvals for early rlt drugs.

The radioligand therapy market size is expected to see rapid growth in the next few years. It will grow to $10.72 billion in 2030 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to development of novel alpha and beta emitters, expansion of combined emission therapies, integration with precision oncology, rising clinical trials for neurological and cardiovascular applications, increasing investment in home care and outpatient rlt services. Major trends in the forecast period include increasing adoption of targeted radioligand therapy for oncology, expansion of alpha and beta emitter-based therapies, integration of radioligand therapy with personalized medicine approaches, growth in hospital and research institution-based rlt programs, rising focus on minimizing side effects and enhancing patient outcomes.

The upsurge in cancer incidence is anticipated to boost the radioligand therapy market ahead. Cancer involves runaway abnormal cell proliferation that infiltrates nearby areas and metastasizes. Its rise links to prolonged environmental toxin exposure harming DNA, impairing cells, and spurring rogue growth. Radioligand therapy combats cancer by channeling radiation via receptor-binding ligands to zap tumors precisely, sparing healthy tissue for internal cell kill. For example, in October 2025, the National Health Service (NHS), a UK public health body, recorded 354,820 new cases in 2023-972 daily, up 8,605 from 2022. Thus, the climbing cancer incidence is fueling the radioligand therapy market.

Prominent companies in the radioligand therapy market are advancing setups like specialized radioligand therapy facilities to optimize output, quality, and safety in crafting and supplying pinpoint cancer drugs. Radioligand therapy facilities are dedicated hubs managing radioactive agents for focused cancer care, equipped with cutting-edge imaging, shielding, expert staff, and rigorous safeguards. For instance, in January 2024, Novartis AG, a Switzerland pharma leader, automated its massive Indiana radioligand therapy (RLT) plant post-FDA commercial nod. Spanning 70,000 square feet, it's Novartis's biggest, most sophisticated RLT site for swift, high-volume runs with full automation, ramping supply for US and Canada patients.

In December 2023, Eli Lilly and Company, a US pharma giant, snapped up POINT Biopharma Global Inc. for $1.4 billion. This bolsters Eli Lilly's oncology range with top-tier radioligand tech for sharper cancer precision meds. POINT Biopharma Global Inc. is a US firm honing radioligand cancer therapies.

Major companies operating in the radioligand therapy market are Novartis AG, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Telix Pharmaceuticals, Mariana Oncology Inc., AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C-Ray Therapeutics Inc.

North America was the largest region in the radioligand therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radioligand therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the radioligand therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The radioligand therapy market consists of revenues earned by entities by providing services such as targeted treatment services, diagnostic imaging, and clinical and infrastructure services. The market value includes the value of related goods sold by the service provider or included within the service offering. The radioligand therapy market also includes sales of somatostatin receptor ligands, radiolabeled bombesin analogs, radiolabeled monoclonal antibodies, and prostate-specific membrane antigen (PSMA)-targeted ligands. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Radioligand Therapy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses radioligand therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for radioligand therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The radioligand therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type Of Radioligand: Alpha Emitters; Beta Emitters; Auger Emitters; Combined Emissions
• 2) By Molecular Target: Hormone Receptors; Growth Factor Receptors; Antigen Tumor Markers; Other Molecular Targets
• 3) By Route Of Administration: Intravenous (IV); Intramuscular (IM); Subcutaneous; Oral
• 4) By Application: Oncology; Cardiovascular Disorders; Neurological Disorders; Infectious Diseases
• 5) By End-User: Hospitals; Diagnostic Laboratories; Research Institutions; Home Care Settings
• Subsegments:
• 1) By Alpha Emitters: Actinium-225 (Ac-225); Radium-223 (Ra-223); Astatine-211 (At-211); Bismuth-213 (Bi-213)
• 2) By Beta Emitters: Lutetium-177 (Lu-177); Iodine-131 (I-131); Yttrium-90 (Y-90); Samarium-153 (Sm-153)
• 3) By Auger Emitters: Iodine-125 (I-125); Indium-111 (In-111); Gallium-67 (Ga-67); Thallium-201 (Tl-201)
• 4) By Combined Emissions: Terbium-161 (Tb-161); Copper-67 (Cu-67); Rhenium-186 (Re-186); Lead-212 (Pb-212)
• Companies Mentioned: Novartis AG; Lantheus Holdings Inc.; Curium LLC; Eckert & Ziegler Strahlen- und Medizintechnik AG; Telix Pharmaceuticals; Mariana Oncology Inc.; AdvanCell Pty Ltd.; Evergreen Theragnostics Inc.; Fusion Pharmaceuticals Inc.; RadioMedix Inc.; Ariceum Therapeutics GmbH; Radiopharm Theranostics Limited; Convergent Therapeutics Inc.; C-Ray Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Radioligand Therapy Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Radioligand Therapy Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Radioligand Therapy Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Radioligand Therapy Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Artificial Intelligence & Autonomous Intelligence
  • 4.1.5 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Increasing Adoption Of Targeted Radioligand Therapy For Oncology
  • 4.2.2 Expansion Of Alpha And Beta Emitter-Based Therapies
  • 4.2.3 Integration Of Radioligand Therapy With Personalized Medicine Approaches
  • 4.2.4 Growth In Hospital And Research Institution-Based RLT Programs
  • 4.2.5 Rising Focus On Minimizing Side Effects And Enhancing Patient Outcomes

5. Radioligand Therapy Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Diagnostic Laboratories
• 5.3 Research Institutions
• 5.4 Home Care Settings
• 5.5 Specialty Cancer Centers

6. Radioligand Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Radioligand Therapy Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Radioligand Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Radioligand Therapy Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Radioligand Therapy Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Radioligand Therapy Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Radioligand Therapy Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Radioligand Therapy Market Segmentation

• 9.1. Global Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Alpha Emitters, Beta Emitters, Auger Emitters, Combined Emissions
• 9.2. Global Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hormone Receptors, Growth Factor Receptors, Antigen Tumor Markers, Other Molecular Targets
• 9.3. Global Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Intravenous (IV), Intramuscular (IM), Subcutaneous, Oral
• 9.4. Global Radioligand Therapy Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases
• 9.5. Global Radioligand Therapy Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Diagnostic Laboratories, Research Institutions, Home Care Settings
• 9.6. Global Radioligand Therapy Market, Sub-Segmentation Of Alpha Emitters, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Actinium-225 (Ac-225), Radium-223 (Ra-223), Astatine-211 (At-211), Bismuth-213 (Bi-213)
• 9.7. Global Radioligand Therapy Market, Sub-Segmentation Of Beta Emitters, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Lutetium-177 (Lu-177), Iodine-131 (I-131), Yttrium-90 (Y-90), Samarium-153 (Sm-153)
• 9.8. Global Radioligand Therapy Market, Sub-Segmentation Of Auger Emitters, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Iodine-125 (I-125), Indium-111 (In-111), Gallium-67 (Ga-67), Thallium-201 (Tl-201)
• 9.9. Global Radioligand Therapy Market, Sub-Segmentation Of Combined Emissions, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Terbium-161 (Tb-161), Copper-67 (Cu-67), Rhenium-186 (Re-186), Lead-212 (Pb-212)

10. Radioligand Therapy Market Regional And Country Analysis

• 10.1. Global Radioligand Therapy Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Radioligand Therapy Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Radioligand Therapy Market

• 11.1. Asia-Pacific Radioligand Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Radioligand Therapy Market

• 12.1. China Radioligand Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Radioligand Therapy Market

• 13.1. India Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Radioligand Therapy Market

• 14.1. Japan Radioligand Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Radioligand Therapy Market

• 15.1. Australia Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Radioligand Therapy Market

• 16.1. Indonesia Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Radioligand Therapy Market

• 17.1. South Korea Radioligand Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Radioligand Therapy Market

• 18.1. Taiwan Radioligand Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Radioligand Therapy Market

• 19.1. South East Asia Radioligand Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Radioligand Therapy Market

• 20.1. Western Europe Radioligand Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Radioligand Therapy Market

• 21.1. UK Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Radioligand Therapy Market

• 22.1. Germany Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Radioligand Therapy Market

• 23.1. France Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Radioligand Therapy Market

• 24.1. Italy Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Radioligand Therapy Market

• 25.1. Spain Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Radioligand Therapy Market

• 26.1. Eastern Europe Radioligand Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Radioligand Therapy Market

• 27.1. Russia Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Radioligand Therapy Market

• 28.1. North America Radioligand Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Radioligand Therapy Market

• 29.1. USA Radioligand Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Radioligand Therapy Market

• 30.1. Canada Radioligand Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Radioligand Therapy Market

• 31.1. South America Radioligand Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Radioligand Therapy Market

• 32.1. Brazil Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Radioligand Therapy Market

• 33.1. Middle East Radioligand Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Radioligand Therapy Market

• 34.1. Africa Radioligand Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Radioligand Therapy Market Regulatory and Investment Landscape

36. Radioligand Therapy Market Competitive Landscape And Company Profiles

• 36.1. Radioligand Therapy Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Radioligand Therapy Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Radioligand Therapy Market Company Profiles
  • 36.3.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Lantheus Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Curium LLC Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Eckert & Ziegler Strahlen- und Medizintechnik AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Telix Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis

37. Radioligand Therapy Market Other Major And Innovative Companies

• Mariana Oncology Inc., AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C-Ray Therapeutics Inc.

38. Global Radioligand Therapy Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Radioligand Therapy Market

40. Radioligand Therapy Market High Potential Countries, Segments and Strategies

• 40.1 Radioligand Therapy Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Radioligand Therapy Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Radioligand Therapy Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer